Related Experiment Videos
[Lack of therapeutic effect on primary amyloidosis by interferon-alpha]
Z Adam1, J Vorlícek, E Králová
1Klinik für Innere Medizin, Universitätskrankenhauses Bmo, Tschechische Republik.
Abstract:
The therapy of primary amyloidosis is still unsatisfactory. The response rate after cytostatics, dimethylsulphoxide, colchicin and vitamin E is usually low. None of these treatment modalities prolongs significantly the survival in the majority of treated patients. The success of interferon alpha in the maintenance therapy of follicular non-Hodgkin's lymphoma and in the remission of multiple myeloma, as well as successful treatment of primary cryoglobulinemia, brought us to the idea to test interferon alfa in the therapy of primary amyloidosis. Interferon alpha-2b was administered to a patient with three years history of primary amyloidosis. Interferon alpha was used in the dose of 3 x 10(6) i. V. daily for a treatment period of 10 weeks. The evaluation of the response was based on the weekly assessment of the light chain lambda concentration in the morning spot of urine. No significant decrease of the light chain concentration during the course of the therapy was observed. The administration of interferon alpha-2b was interrupted in the 10th week of the therapy because of manic psychosis. The question is, whether a higher dose than 3 x 10(6) IU daily would be able to decrease the light chain production, or if this disease is resistant to interferon alpha therapy. Because of the low incidence of primary amyloidosis, the experiences will be collected on the base of small groups of case reports.
Insights
Investigating interferon alpha for primary amyloidosis yielded unsatisfactory results. The therapy did not significantly decrease light chain levels and caused adverse effects, questioning its efficacy for this rare disease.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Primary amyloidosis therapy remains challenging with limited treatment options.
- Existing treatments like cytostatics and vitamin E show low response rates and minimal survival benefits.
- Interferon alpha has demonstrated success in other hematologic malignancies and autoimmune conditions.
Observation:
- A single patient with primary amyloidosis received interferon alfa-2b (3x10^6 IU daily IV for 10 weeks).
- Treatment efficacy was monitored by weekly urinary light chain lambda concentration.
- The patient experienced manic psychosis, leading to treatment discontinuation in the 10th week.
Findings:
- No significant decrease in urinary light chain lambda concentration was observed during interferon alfa-2b therapy.
- The patient developed manic psychosis as an adverse event, necessitating treatment cessation.
- The study raises questions about optimal dosing or inherent resistance of primary amyloidosis to interferon alfa.
Implications:
- Further research with larger patient cohorts is needed to determine interferon alfa's role in primary amyloidosis.
- Investigating higher doses or alternative treatment strategies may be necessary.
- Understanding treatment resistance and adverse effects is crucial for developing effective therapies for rare diseases like primary amyloidosis.